JAK2 inhibition suppresses IL-6, TNF-α, and the Th1/Th17 response in human allogeneic MLRs. (A) The effect of JAK2 inhibition (TG101348, 1μM) on IL-6 and TNF-α concentrations in the supernatants of allogeneic MLRs compared with DMSO (0.01%). Bar graphs show means ± SD from 5 (IL-6) and 4 (TNF-α) independent experiments; *P < .05; **P = .001-.01 by paired t test. (B) Representative contour plots show the effect of TG101348 (1μM) on allogeneic Th1 and Th17 populations (gating on CD3⁺CD4⁺ and then assessing for IFN-γ and IL-17) compared with DMSO (0.01%) after a 6-day allogeneic MLR of sorted CD4⁺ T cells and cytokine-matured moDCs. (C) The effect of JAK2 inhibition on allogeneic Th1, Th17, and CD4⁺IFN-γ⁺IL-17⁺ populations compared with DMSO. (D) The influence of JAK2 inhibition on CD25 expression, a marker of lymphocyte activation, on allogeneic Th1, Th17, and CD4⁺IFN-γ⁺IL-17⁺ T cells compared with DMSO. Bar graphs show means ± SD from 4 independent experiments; *P < .05; **P = .001-.01; NS, not significant by paired t test.